| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
IFC
|
|
| Hot Topic |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Chemoprevention for breast cancer
19 August 2011
Abstract: Despite the progress that has been made in breast cancer diagnosis and treatment, this disease is still a major health problem, being the most frequently diagnosed cancer and the first leadi...
|
I. Bozovic-Spasojevic,
E. Azambuja,
Worta McCaskill-Stevens,
P. Dinh,
F. Cardoso
et al.
|
329-339
|
|
|
|
New treatment options for patients with metastatic castration-resistant prostate cancer
26 September 2011
Abstract: Chemotherapy for men with metastatic castration-resistant prostate cancer (CRPC) conferred no survival advantage until 2004 when docetaxel was shown to improve survival when compared with mi...
|
Celestia S. Higano
|
340-345
|
|
|
|
Clinical and future applications of high intensity focused ultrasound in cancer
19 September 2011
Abstract: High intensity focused ultrasound (HIFU) or focused ultrasound (FUS) is a promising modality to treat tumors in a complete, non invasive fashion where online image guidance and therapy contr...
|
Osama Al-Bataineh,
Jürgen Jenne,
Peter Huber
|
346-353
|
|
|
|
Options on fertility preservation in female cancer patients
11 November 2011
Abstract: Infertility following treatment of cancer is a quality of survival’s recognized issue and efforts should be made to help young cancer patients retaining their fertility potential. Options to...
|
Kenny A. Rodriguez-Wallberg,
Kutluk Oktay
|
354-361
|
|
| Controversy |
| |
Article Title |
Author(s) |
Pages |
|
|
|
The ethnic divide in breast reconstruction: A review of the current literature and directions for future research
10 February 2012
Abstract: Ethnic disparities exist in many areas of breast cancer treatment. When a mastectomy is necessary, the next discussion in the overall surgical management often focuses on breast reconstructi...
|
Jonas A. Nelson,
Priscilla Nelson,
Julia Tchou,
Joseph M. Serletti,
Liza C. Wu
et al.
|
362-367
|
|
| Antitumour Treatment |
| |
Article Title |
Author(s) |
Pages |
|
|
|
A role for maintenance therapy in managing sarcoma
16 August 2011
Summary: Despite the use of recommended chemotherapy regimens, patients with metastatic sarcomas have a poor prognosis. To date, the median overall survival for metastatic disease remains less than 18...
|
Isabelle Ray-Coquard,
Axel Le Cesne
|
368-378
|
|
|
|
Electrochemotherapy of chest wall breast cancer recurrence
19 August 2011
Abstract: Chest wall breast cancer recurrence after mastectomy is a disease difficult to treat. Its incidence varies between 5% and 30% in different subset of patients. When possible, radical surgical...
|
Gregor Sersa,
Tanja Cufer,
Snezna Marija Paulin,
Maja Cemazar,
Marko Snoj
et al.
|
379-386
|
|
|
|
Docetaxel combined with targeted therapies in metastatic breast cancer
29 August 2011
Abstract: The treatment of metastatic breast cancer (MBC) is essentially palliative and should be based on hormone therapy or optimized chemotherapy designed to delay disease progression and maximize ...
|
Javier Cortes,
Henri Roché
|
387-396
|
|
|
|
Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice
07 September 2011
Abstract: More therapeutic options are now available than ever before for patients with metastatic colorectal cancer (mCRC) and, as such, treatment decisions have become more complex. A multidisciplin...
|
Marc Peeters,
Timothy Price
|
397-406
|
|
|
|
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
10 October 2011
Abstract: The bone marrow microenvironment provides a site for cancer cells to evade systemic anticancer therapy. Dormant tumor micrometastases are believed to be the source of disease persistence and...
|
Michael Gnant,
Philippe Clézardin
|
407-415
|
|
|
|
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
28 November 2011
Abstract: Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase have been termed ‘oncogene addicted’ to reflect their depende...
|
Jean-Charles Soria,
Tony S. Mok,
Federico Cappuzzo,
Pasi A. Jänne
|
416-430
|
|
|
|
Recommendations for the optimal management of early and advanced urothelial carcinoma
24 November 2011
Abstract: The field of urothelial carcinoma has shown considerable advances in terms of diagnosis, staging, and treatment. The increasing knowledge of molecular pathways and genes involved in the occu...
|
Daniel Castellano,
Joan Carles,
Emilio Esteban,
José Manuel Trigo,
Miguel Ángel Climent,
José Pablo Maroto,
Xavier García del Muro,
Albert Font,
Luis Paz-Ares,
José Ángel Arranz,
Joaquim Bellmunt
et al.
|
431-441
|
|
| Laboratory-Clinic Interface |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Pharmacogenetics of anti-estrogen treatment of breast cancer
15 September 2011
Abstract: A major effort is underway to select genetic polymorphisms potentially relevant to the clinical efficacy and safety of endocrine treatment of breast cancer. Genetic factors of the host that ...
|
Marzia Del Re,
Angela Michelucci,
Paolo Simi,
Romano Danesi
|
442-450
|
|
|
|
The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer
26 September 2011
Abstract: Colorectal cancer progression and survival is dependent on complex interactions between the tumour and the host. The pronounced local inflammatory response in and around the tumour is though...
|
C.S.D. Roxburgh,
D.C. McMillan
|
451-466
|
|
|
|
Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance
31 October 2011
Abstract: The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors (GIST). Currently, imatinib mesy...
|
Shreyaskumar Patel
|
467-472
|
|
| New Drugs |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications
10 October 2011
Abstract: In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the cli...
|
Aspasia Soultati,
Giannis Mountzios,
Chrysoula Avgerinou,
George Papaxoinis,
Dimitrios Pectasides,
Meletios-Athanassios Dimopoulos,
Christos Papadimitriou
et al.
|
473-483
|
|
|
|
A preclinical and clinical review of aflibercept for the management of cancer
24 January 2012
Abstract: Aflibercept, also known as vascular endothelial growth factor (VEGF)–Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only al...
|
Andrew Gaya,
Vivien Tse
|
484-493
|
|
|
|
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
06 February 2012
Summary: Overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in metastatic breast cancer. While the introduction of HER2-targeted therapies, such as the mon...
|
Ahmad Awada,
Ivana Bozovic-Spasojevic,
Louis Chow
|
494-504
|
|
| Complications of Treatment |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
21 November 2011
Summary: Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequen...
|
J.M. Baas,
L.L. Krens,
H.-J. Guchelaar,
J. Ouwerkerk,
F.A de Jong,
A.P.M. Lavrijsen,
H. Gelderblom
et al.
|
505-514
|
|
| Tumour Reviews |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Cancer stem cells hypothesis and stem cells in head and neck cancers
26 December 2011
Summary: There is increasing evidence that the growth and spread of cancer is driven by a small subpopulation of cancer cells, defined as cancer stem cells (CSCs). Recent data indicate that the initia...
|
Giuditta Mannelli,
Oreste Gallo
|
515-539
|
|
|
|
State-of-the-art classification and multimodality treatment of malignant thymoma
16 January 2012
Abstract: Thymomas are the most common tumors of the anterior mediastinum. Classification, treatment options and understanding of the pathophysiology of thymoma have changed over the past years. It is...
|
Hannah Koppitz,
Jürgen K. Rockstroh,
Heinrich Schüller,
Jens Standop,
Dirk Skowasch,
Hans Konrad Müller-Hermelink,
Ingo G.H. Schmidt-Wolf
et al.
|
540-548
|
|
|
|
Uveal melanoma
24 January 2012
Abstract: Uveal melanoma, which arises from melanocytes residing in the stroma, is the most common primary intraocular tumor in adults. Up to 50% of patients with primary uveal melanoma will ultimatel...
|
Francesco Spagnolo,
Graziano Caltabiano,
Paola Queirolo
|
549-553
|
|
| General and Supportive Care |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials
02 August 2011
Abstract: Background: Health-related quality of life (HRQOL) parameters are often used as end points in phase III trials in advanced breast cancer. The frequency and correlates of significant gains in...
|
Krzysztof Adamowicz,
Jacek Jassem,
Artur Katz,
Everardo D. Saad
|
554-558
|
|
